WOODSTOCK, Ga.--(BUSINESS WIRE)--Tissue Regeneration Technologies, LLC (TRT) and Nonvasiv, LLC (Nonvasiv) are pleased to announce they have agreed to merge, subject to certain conditions and due diligence by both parties. This is a merger between the strategic and the tactical. TRT is largely focused on long-term value for its investors by investing in research and development, clinical studies, and relationships. TRT has raised approximately $10 million in private equity since its inception for these purposes. Nonvasiv is capitalizing on business segments, such as the veterinary market, that are immediately profitable. “This merger is the ideal convergence of time, talent, and technology,” stated TRT president, John Warlick.
